Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin’s Lymphoma

DISEASE CHARACTERISTICS:

Histologically confirmed relapsed or refractory grade I, II, or III non-Hodgkin's lymphoma (NHL), including follicular, small lymphocytic, or marginal zone/MALT lymphoma

Previously treated with radiotherapy, immunotherapy, and/or chemotherapy for NHL

Progression of disease or no response since last treatment for NHL
1D10+ lymphoma by immunohistochemistry or flow cytometry
Bidimensionally measurable disease at least 2 cm in a single dimension
No CNS metastases
Circulating tumor cells no greater than 5,000/mm^3

PATIENT CHARACTERISTICS:

Age:

18 and over

Performance status:

ECOG 0-2

Life expectancy:

At least 3 months

Hematopoietic:

Platelet count at least 75,000/mm^3 (unless disease related)
Neutrophil count at least 1,000/mm^3 (unless disease related)
Hemoglobin greater than 8.0 g/dL

Hepatic:

Bilirubin less than 2.5 mg/dL
SGOT less than 4 times upper limit of normal

Renal:

Creatinine less than 2.5 mg/dL

Cardiovascular:

No clinically significant cardiac disease (New York Heart Association class III or IV)
No evidence of myocardial infarction or cardiac arrhythmia (unless surgically repaired) within the past 6 months

Pulmonary:

No clinically significant pulmonary disease

Other:

No other malignancy within the past 2 years except non-melanoma skin cancer or carcinoma in situ
No significant psychiatric or CNS impairment
No active serious infection
Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective contraception during and for 1 month after study
Negative anti-Hu1D10 antibody response (HAHA/HAMA)
HIV negative

PRIOR CONCURRENT THERAPY:

Biologic therapy:

See Disease Characteristics
At least 4 weeks since prior interferon therapy
At least 3 months since prior immunotherapy
No prior monoclonal antibody Hu1D10

Chemotherapy:

See Disease Characteristics
At least 4 weeks since prior cytotoxic chemotherapy

Endocrine therapy:

At least 4 weeks since prior corticosteroids (more than 10 mg prednisone/day)
No concurrent corticosteroids at more than 10 mg prednisone/day for pre-existing diseases or adverse reactions

Radiotherapy:

See Disease Characteristics
At least 4 weeks since prior external beam radiotherapy
At least 3 months since prior radioimmunotherapy

Surgery:

Not specified

Other:

No other concurrent lymphoma therapy